display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HER2-positivebreast cancer - HR positive
la/mBC - HER2 positive - 1st Line (L1)la/mBC - HR-positive - 1st line (L1)
trastuzumab plus endocrine therapy SYSUCC-002 SYSUCC-002

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons